Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, however in Europe it is only approved for patients who are not eligible for HSCT.
Voso, M.t., Leone, G., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., et al. (2017). Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. ANNALS OF ONCOLOGY, 28(7), 1547-1553 [10.1093/annonc/mdx154].
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
VOSO, MARIA TERESA;
2017-07-01
Abstract
Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, however in Europe it is only approved for patients who are not eligible for HSCT.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Voso et al, Ann Oncol 2017.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
2.98 MB
Formato
Adobe PDF
|
2.98 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
